A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy

BACKGROUND: The outcomes of advanced non-small cell lung cancer (NSCLC) patients after first- or second-line therapy are still discouraging due to a lack of effective treatment strategies. As a novel oral anti-angiogenesis drug, apatinib, approved by the National Medical Products Administration of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shuang, Ou, Wuling, Zhong, Yi, Zhu, Xianmin, Cai, Qian, Zhang, Jing, Ran, Fengming, Qian, Yu, Wang, Jun, Hu, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848392/
https://www.ncbi.nlm.nih.gov/pubmed/35282037
http://dx.doi.org/10.21037/atm-22-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848392/
https://www.ncbi.nlm.nih.gov/pubmed/35282037
http://dx.doi.org/10.21037/atm-22-79

Ejemplares similares